tiprankstipranks
Axsome Therapeutics Inc. (AXSM)
NASDAQ:AXSM
US Market
AXSM
Axsome Therapeutics
RESEARCH TOOLSreports
Want to see AXSM full AI Analyst Report?

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2,369 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
19Ratings
Strong Buy
18 Buy
1 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$261.88
▲(38.57% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $261.88 with a high forecast of $310.00 and a low forecast of $200.00. The average price target represents a 38.57% change from the last price of $188.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"101":"$101","206":"$206","311":"$311","153.5":"$153.5","258.5":"$258.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$310.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":261.88235294117646,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$261.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[101,153.5,206,258.5,311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.53,214.48923076923077,222.44846153846154,230.40769230769232,238.3669230769231,246.32615384615386,254.2853846153846,262.2446153846154,270.20384615384614,278.1630769230769,286.1223076923077,294.08153846153846,302.04076923076923,{"y":310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.53,210.78787330316743,215.04574660633483,219.30361990950226,223.5614932126697,227.8193665158371,232.07723981900452,236.33511312217195,240.59298642533935,244.85085972850678,249.1087330316742,253.3666063348416,257.62447963800906,{"y":261.88235294117646,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.53,206.02769230769232,205.5253846153846,205.02307692307693,204.52076923076922,204.01846153846154,203.51615384615386,203.01384615384615,202.51153846153846,202.00923076923078,201.50692307692307,201.0046153846154,200.50230769230768,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$310.00Average Price Target$261.88Lowest Price Target$200.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$258
Buy
36.52%
Upside
Reiterated
05/11/26
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$228→$310
Buy
64.03%
Upside
Assigned
05/08/26
Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$267
Buy
41.28%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM) and Kymera Therapeutics (NASDAQ: KYMR)
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$270→$290
Buy
53.45%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $270 from $250 at H.C. WainwrightAxsome Therapeutics price target raised to $270 from $250 at H.C. Wainwright
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$242→$302
Buy
59.80%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $302 from $242 at RBC CapitalAxsome Therapeutics price target raised to $302 from $242 at RBC Capital
Deutsche Bank Analyst forecast on AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$281→$280
Buy
48.16%
Upside
Assigned
05/05/26
Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$217→$242
Hold
28.05%
Upside
Assigned
05/05/26
Morgan Stanley Sticks to Its Hold Rating for Axsome Therapeutics (AXSM)
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$225→$255
Buy
34.93%
Upside
Assigned
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
Robert W. Baird Analyst forecast on AXSM
Brian Skorney
Robert W. Baird
Robert W. Baird
$241→$246
Buy
30.17%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird
Guggenheim Analyst forecast on AXSM
Yatin Suneja
Guggenheim
Guggenheim
$245→$260
Buy
37.57%
Upside
Reiterated
05/04/26
Axsome Therapeutics price target raised to $260 from $245 at GuggenheimAxsome Therapeutics price target raised to $260 from $245 at Guggenheim
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN) and Axsome Therapeutics (NASDAQ: AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$214→$276
Buy
46.04%
Upside
Reiterated
05/04/26
Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target
Cantor Fitzgerald Analyst forecast on AXSM
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$234→$272
Buy
43.92%
Upside
Reiterated
05/04/26
Axsome Therapeutics price target raised to $272 from $234 at Cantor FitzgeraldAxsome Therapeutics price target raised to $272 from $234 at Cantor Fitzgerald
TD Cowen Analyst forecast on AXSM
Joseph Thome
TD Cowen
TD Cowen
$215→$255
Buy
34.93%
Upside
Assigned
05/01/26
Analysts Offer Insights on Healthcare Companies: Evotec AG (NASDAQ: EVO), Twist Bioscience (NASDAQ: TWST) and Axsome Therapeutics (NASDAQ: AXSM)
Jefferies Analyst forecast on AXSM
Andrew Tsai
Jefferies
Jefferies
$245→$200
Buy
5.83%
Upside
Reiterated
05/01/26
Axsome Therapeutics price target raised to $275 from $245 at JefferiesAxsome Therapeutics price target raised to $275 from $245 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$258
Buy
36.52%
Upside
Reiterated
05/11/26
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$228→$310
Buy
64.03%
Upside
Assigned
05/08/26
Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$267
Buy
41.28%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM) and Kymera Therapeutics (NASDAQ: KYMR)
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$270→$290
Buy
53.45%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $270 from $250 at H.C. WainwrightAxsome Therapeutics price target raised to $270 from $250 at H.C. Wainwright
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$242→$302
Buy
59.80%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $302 from $242 at RBC CapitalAxsome Therapeutics price target raised to $302 from $242 at RBC Capital
Deutsche Bank Analyst forecast on AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$281→$280
Buy
48.16%
Upside
Assigned
05/05/26
Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$217→$242
Hold
28.05%
Upside
Assigned
05/05/26
Morgan Stanley Sticks to Its Hold Rating for Axsome Therapeutics (AXSM)
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$225→$255
Buy
34.93%
Upside
Assigned
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
Robert W. Baird Analyst forecast on AXSM
Brian Skorney
Robert W. Baird
Robert W. Baird
$241→$246
Buy
30.17%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird
Guggenheim Analyst forecast on AXSM
Yatin Suneja
Guggenheim
Guggenheim
$245→$260
Buy
37.57%
Upside
Reiterated
05/04/26
Axsome Therapeutics price target raised to $260 from $245 at GuggenheimAxsome Therapeutics price target raised to $260 from $245 at Guggenheim
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN) and Axsome Therapeutics (NASDAQ: AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$214→$276
Buy
46.04%
Upside
Reiterated
05/04/26
Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target
Cantor Fitzgerald Analyst forecast on AXSM
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$234→$272
Buy
43.92%
Upside
Reiterated
05/04/26
Axsome Therapeutics price target raised to $272 from $234 at Cantor FitzgeraldAxsome Therapeutics price target raised to $272 from $234 at Cantor Fitzgerald
TD Cowen Analyst forecast on AXSM
Joseph Thome
TD Cowen
TD Cowen
$215→$255
Buy
34.93%
Upside
Assigned
05/01/26
Analysts Offer Insights on Healthcare Companies: Evotec AG (NASDAQ: EVO), Twist Bioscience (NASDAQ: TWST) and Axsome Therapeutics (NASDAQ: AXSM)
Jefferies Analyst forecast on AXSM
Andrew Tsai
Jefferies
Jefferies
$245→$200
Buy
5.83%
Upside
Reiterated
05/01/26
Axsome Therapeutics price target raised to $275 from $245 at JefferiesAxsome Therapeutics price target raised to $275 from $245 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months
Leonid TimashevRBC Capital
Success Rate
20/27 ratings generated profit
74%
Average Return
+12.26%
Copying Leonid Timashev's trades and holding each position for 3 Months would result in 74.07% of your transactions generating a profit, with an average return of +12.26% per trade.
1 Year
Ami FadiaNeedham
Success Rate
18/18 ratings generated profit
100%
Average Return
+56.94%
Copying Ami Fadia's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +56.94% per trade.
2 Years
Marc GoodmanLeerink Partners
Success Rate
32/32 ratings generated profit
100%
Average Return
+114.26%
Copying Marc Goodman's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +114.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
2
3
4
2
Buy
42
41
38
30
36
Hold
1
2
2
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
45
43
35
40
In the current month, AXSM has received 38 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 261.88.
Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.84 with a range of -$1.60 to -$0.05. The previous quarter’s EPS was -$1.26. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s earnings estimate for AXSM is -$0.84 with a range of -$1.60 to -$0.05. The previous quarter’s EPS was -$1.26. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $222.25M with a range of $206.40M to $257.50M. The previous quarter’s sales results were $191.20M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s sales forecast for AXSM is $222.25M with a range of $206.40M to $257.50M. The previous quarter’s sales results were $191.20M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc.’s 12-month average price target is 261.88.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc. has 38.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc. has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc.’s price target?
            The average price target for Axsome Therapeutics Inc. is 261.88. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $310.00 ,the lowest forecast is $200.00. The average price target represents 38.57% Increase from the current price of $188.99.
              What do analysts say about Axsome Therapeutics Inc.?
              Axsome Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.